Research programme: protein-arginine deiminase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: protein-arginine deiminase inhibitors - Bristol-Myers Squibb

Alternative Names: PAD inhibitors - Bristol-Myers Squibb

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Padlock Therapeutics
  • Developer Bristol-Myers Squibb; Evotec AG
  • Class
  • Mechanism of Action Protein-arginine deiminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders

Most Recent Events

  • 28 May 2018 No recent reports of development identified for research development in Autoimmune-disorders in USA
  • 01 Apr 2016 Padlock Therapeutics has been acquired by and merged into Bristol-Myers Squibb
  • 28 May 2015 Padlock Therapeutics in-licenses intellectual property, compounds, assays, data and crystal structures from GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top